MELD 3.0: Exploring and expanding its utility beyond transplantation Authors: Pavan Kumar Reddy Kalluru, Hassan Emad Buhulaigah, Kishan Kumar Allikesam, Deekshitha Kuchi, Abdul Muqtadir, Nirmal Onteddu, Apoorva Cherukuri, Teja Allagadda, Madhusree Kamakkagari, Hossein Rajali Published: 2026 ABSTRACT The model for end-stage liver disease (MELD) score has evolved into a cornerstone of liver transplantation prioritization. With the recent development of MELD 3.0, which incorporates serum albumin and sex-adjusted variables, its predictive accuracy and applicability have expanded significantly. This review examines the potential clinical applications of MELD 3.0 beyond transplant selection, highlighting its utility as a broader prognostic tool across various hepatic and systemic conditions. Data from multiple domains suggest that MELD 3.0 provides meaningful clinical insight. In orthotopic heart transplantation, MELD 3.0 has demonstrated superior predictive power for short-term mortality and postoperative intensive care unit resource utilization. In acute variceal hemorrhage, it has maintained good discriminatory ability, although calibration challenges limit its use as a standalone tool. Among patients with hepatocellular carcinoma and renal insufficiency, MELD 3.0 has shown moderate predictive value for survival but has been outperformed by albumin-bilirubin-based models. In transjugular intrahepatic portosystemic shunt procedures, MELD 3.0 has effectively stratified pre- and postprocedural risk, enhancing dynamic patient monitoring and decisions regarding transplant timing. For alcohol-associated hepatitis, MELD 3.0 has surpassed older models in predicting mortality and the need for renal replacement therapy, particularly in women and malnourished patients. In oncology, MELD 3.0 has contributed to mortality risk assessment in hepatic visceral crisis when combined with inflammatory markers. However, its performance has been less robust in hepatic hydrothorax, where mortality has occurred at lower MELD scores, and in spontaneous bacterial peritonitis, where it has performed comparably to other MELD variants. Collectively, these findings underscore the growing relevance of MELD 3.0 as a generalizable risk stratification tool across acute and chronic liver-related conditions. Although further prospective validation is warranted, its incorporation into routine hepatology and multidisciplinary care pathways may enhance prognostic precision and inform therapeutic decision-making beyond transplantation. Points to Note Synthesis of Current Evidence: MELD 3.0 shows prognostic value beyond transplantation, including TIPS, alcohol-associated hepatitis, SBP, cardiac transplantation, HCC, and oncology-related hepatic dysfunction.Major Controversies: Its performance varies by setting and may be limited by calibration issues, albumin-related confounding, and underestimation of risk in hepatic hydrothorax.Future Directions: Large prospective, multicenter studies are needed to validate context-specific use and compare MELD 3.0 with existing scores. Synthesis of Current Evidence: MELD 3.0 shows prognostic value beyond transplantation, including TIPS, alcohol-associated hepatitis, SBP, cardiac transplantation, HCC, and oncology-related hepatic dysfunction. Synthesis of Current Evidence: MELD 3.0 shows prognostic value beyond transplantation, including TIPS, alcohol-associated hepatitis, SBP, cardiac transplantation, HCC, and oncology-related hepatic dysfunction. Major Controversies: Its performance varies by setting and may be limited by calibration issues, albumin-related confounding, and underestimation of risk in hepatic hydrothorax. Major Controversies: Its performance varies by setting and may be limited by calibration issues, albumin-related confounding, and underestimation of risk in hepatic hydrothorax. Future Directions: Large prospective, multicenter studies are needed to validate context-specific use and compare MELD 3.0 with existing scores. Future Directions: Large prospective, multicenter studies are needed to validate context-specific use and compare MELD 3.0 with existing scores. Lay Summary The MELD score is a well-known medical system used worldwide to rank patients who urgently need a liver transplant. Recently, a newer and more accurate version called MELD 3.0 was developed, which now takes into account gender differences and protein levels in the blood. While originally designed only for liver transplants, this review study shows that MELD 3.0 is highly valuable for many other medical conditions. We found that this new score helps doctors accurately predict health risks in patients undergoing heart transplants, those suffering from severe alcohol-related liver disease, and patients undergoing specialized liver procedures (like TIPS). However, it is slightly less precise for certain specific conditions, such as liver cancer or severe fluid buildup in the lungs. Overall, our study highlights that MELD 3.0 is not just a tool for transplant lists. It is a powerful, everyday calculator that can help doctors in various fields spot high-risk patients earlier, predict complications, and make better treatment decisions for patients with both liver and heart diseases. Introduction The model for end-stage liver disease (MELD) score was first formulated in the early 21st century to assess mortality risk in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS). This scoring system, which is based on objective laboratory criteria, quickly gained widespread adoption for prioritizing liver transplantation, ultimately superseding the more subjective Child-Turcotte-Pugh (CTP) classification for organ allocation.[1,2] Subsequently, multiple modifications were made to the original MELD score to capture the evolving nature of liver disease, culminating in the proposal of MELD 3.0. MELD 3.0 is the most recent update in this arena and was designed to address long-standing inequalities in liver transplant allocation, particularly for women.[3] This improvement was achieved by incorporating serum albumin and sex variables, along with improved calibration of other variables, compared with the original MELD score.[3] However, it is important to note that MELD 3.0 has not yet been prospectively validated across all geographic regions, ethnic groups, or transplantation settings, particularly between living-donor liver transplantation (LDLT) and deceased-donor liver transplantation (DDLT). Therefore, its universal applicability should be interpreted with caution, and further large-scale, multicenter validation is warranted before widespread clinical adoption. Although the MELD 3.0 score was originally developed in the transplantation setting, its refinement raises an important question: Can this tool be adapted for broader use in clinical hepatology and general medicine? In recent years, there has been a growing trend toward using scoring systems such as MELD 3.0 across a variety of clinical settings rather than restricting them to a single, isolated purpose. This shift has been made possible because the components of the MELD 3.0 scoring system reflect broader systemic dysfunction, making it applicable beyond its original context. Notably, the precursors to MELD 3.0, MELD and MELD-Na, have already demonstrated utility beyond liver transplantation.[4,5] This broader application may be even more significant and precise with MELD 3.0 because of its superior calibration. Albumin, in particular, adds a valuable dimension by indirectly reflecting nutritional reserve and systemic inflammation, two critical elements in evaluating frailty and long-term prognosis.[3] However, the inclusion of albumin also introduces context-dependent limitations. Exogenous albumin administration, which is commonly used in acute liver decompensation, alcoholic hepatitis, and oncologic settings, may transiently elevate serum albumin levels, thereby artificially lowering the calculated MELD 3.0 score. This effect may mask the true severity of hepatic dysfunction in acute or intervention-intensive clinical scenarios. Accordingly, the prognostic performance of MELD 3.0 must be interpreted in light of treatment-related confounding, particularly in settings where albumin infusion is frequent. This narrative review explores the evolving role of MELD 3.0 across various clinical settings while also drawing comparisons with other scoring systems where applicable. Discussion Orthotopic Heart Transplantation Orthotopic heart transplantation (HTx) is considered the gold standard for treating end-stage heart failure (HF).[6] Assessing postoperative outcomes is critical in these major procedures, and various tools have been used for this purpose. The use of MELD 3.0 in this clinical setting is particularly useful and feasible because of the nature of its components, as well as the frequent coexistence of heart failure and liver disease, which share several risk factors, including alcohol abuse, drug abuse, chronic inflammation, autoimmune disorders, and infections.[7] In addition, patients with heart failure are at increased risk of developing hepatic dysfunction, which can adversely affect transplant outcomes. In 2012, Chokshi et al.[8] studied 617 adult patients to evaluate 30-day outcomes and 10-year survival rates. This study used MELD or modified MELD, a score in which albumin replaced INR, and found that high pretransplant scores were associated with worse 30-day outcomes and lower 10-year survival rates. In 2018, a study conducted in Brazil used MELD excluding INR (MELD-IX), another MELD-based model, and found that higher preoperative scores were associated with a poor prognosis in patients undergoing HTx.[9] Following this research trajectory, Ptak et al.[10] conducted a 2024 study using MELD 3.0 in 106 patients with advanced HF undergoing HTx. The primary endpoint of the study was 6-month mortality, and the secondary endpoint was the length of ICU stay after HTx. MELD 3.0 scores for all patients were calculated 1 month before HTx and again 1 week after the procedure. According to the study results, 16% of patients died within 6 months after HTx, and all of them had a significantly higher mean 1-week post-HTx MELD 3.0 score of 18.3 (range: 14.5–22.7) compared with the mean score of 13.9 (range: 9.5–16.4) among survivors, with p<0.01. Receiver operating characteristic (ROC) analysis identified a MELD 3.0 cutoff point of 17.3, and patients exceeding this threshold had longer ICU stays, with a mean difference of 5 days (p=0.01). Conversely, pre-HTx MELD 3.0 scores did not differ significantly between the two groups (p=0.36), suggesting limited prognostic value in the preoperative phase. In summary, the MELD 3.0 score appears to be a promising postoperative prognostic indicator for patients with advanced HF undergoing HTx, and its ability to predict posttransplant ICU burden emphasizes the importance of postoperative risk stratification in improving outcomes. However, in this study, MELD 3.0 was analyzed without direct comparison with other MELD score variants. This limitation restricts the interpretability of the findings, as assessing a single prognostic model in isolation does not allow determination of whether MELD 3.0 truly outperforms other scores. Therefore, the results should be viewed as demonstrating the potential applicability of MELD 3.0 in this population rather than establishing its superiority. Moreover, the study did not report baseline hepatic characteristics or specify whether patients undergoing HTx had preexisting liver disease. As not all HTx recipients have liver pathology, this omission makes it difficult to determine whether MELD 3.0 functioned as a true cardiometabolic prognostic score or whether its predictive ability was partly driven by underlying hepatic dysfunction. In addition, the available evidence to date is confined to this single study, which limits generalizability, and further research is warranted for validation. Acute Variceal Hemorrhage With a substantial 6-week mortality risk of 15%–25%, acute variceal hemorrhage (AVH) is one of the most serious decompensating events in patients with cirrhosis.[11,12] Accurately predicting short-term mortality in these patients is crucial for clinical decision-making, risk stratification, and therapeutic intervention planning. Although conventional prognostic models, such as MELD and Child-Turcotte-Pugh (CTP) scores, have been widely used for mortality prediction in AVH, the advent of MELD 3.0 has prompted research into its relative utility in this acute context.[13] One of the first systematic assessments of the ability of MELD 3.0 to predict 6-week mortality after variceal bleeding was conducted by Buckholz and colleagues in a multicenter study involving five academic medical centers and a US cohort of 354 patients with endoscopically confirmed AVH.[14] Compared with the classic MELD score (AUROC 0.76) and CTP score (AUROC 0.77), MELD 3.0 demonstrated an AUROC of 0.77 for identifying patients at increased risk of mortality. All three models showed statistically equivalent discriminatory performance, suggesting that the enhanced components of MELD 3.0 do not significantly improve mortality prediction accuracy over existing models in the AVH setting. The study also revealed important calibration differences between models when externally validated across multiple centers. After recalibration, the CTP score demonstrated superior calibration and overall performance compared with both MELD 3.0 and traditional MELD scores. The recalibrated MELD 3.0 showed acceptable calibration (p=0.26) but exhibited increased heterogeneity in observed mortality at higher scores across different cohorts, potentially limiting its reliability in clinical practice. The acute nature of variceal bleeding may cause components of the MELD 3.0 score, such as sodium and creatinine levels, to deviate substantially from a patient’s chronic baseline values during hospitalization. This deviation may misrepresent the patient’s underlying organ function.[14] The study also established clinically relevant mortality thresholds. A MELD 3.0 score of less than 12 corresponded to less than 5% 6-week mortality, whereas a score greater than 20 corresponded to greater than 20% 6-week mortality. However, these findings are limited by calibration challenges in acute settings.[14] Hepatocellular Carcinoma Patients with Renal Insufficiency There is a bidirectional relationship between kidney dysfunction and hepatocellular carcinoma (HCC).[15] Studies have shown that more than 25% of individuals with HCC have renal insufficiency (RI), often developing as a result of cirrhosis.[16] It is well known that splanchnic vasodilation occurs in patients with cirrhosis, resulting in reduced effective arterial blood volume. This, in turn, triggers compensatory vasoconstrictive mechanisms, ultimately causing renal hypoperfusion.[16,17] Conversely, growing evidence suggests that patients with end-stage renal disease (ESRD) are at increased risk of developing liver cancer.[18,19] To evaluate how well liver function models predict outcomes in this high-risk patient population, Ho et al.[20] conducted a cohort study evaluating five liver reserve models in patients with HCC and RI: albumin-bilirubin (ALBI), easy ALBI, platelet-albumin-bilirubin (PALBI), platelet-albumin (PAL), and MELD 3.0. The study included 1,120 patients and assessed the performance of these models in stratifying overall survival. Although all five models significantly predicted survival (all p<0.001), their prognostic accuracy varied. This was assessed using the corrected Akaike information criterion (AICc) and the homogeneity index. A lower AICc and a higher homogeneity index indicate better model performance. Among the models, MELD 3.0 showed moderate predictive value, with an AICc of 11,364 and a homogeneity score of 156.026. However, it was outperformed by the ALBI-based models. The ALBI model demonstrated the best prognostic accuracy, with the lowest AICc (11,281.79) and the highest homogeneity index (239.031), making it the most reliable tool for predicting overall survival in patients with HCC and RI. Transjugular Intrahepatic Portosystemic Shunt Creation Researchers at the Mayo Clinic created the first MELD score in the early 2000s with the specific purpose of predicting short-term mortality in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).[1] The MELD score was then adopted in 2002 to prioritize liver transplant allocation and subsequently became an established tool in transplant medicine.[2] The original use of the MELD score in TIPS-related risk stratification has gradually evolved, and more recent versions have been tailored for transplantation. This section revisits the foundational purpose of the MELD score by evaluating the performance of the most recent version, MELD 3.0, in the context of TIPS procedures. TIPS achieves high technical success rates of 94%–95% and clinical success in 92% of cases.[21] However, long-term outcomes remain variable, with survival rates of 87.5% at 1 month, 66.8% at 1 year, and 44.7% at 5 years after the procedure.[22,23] These outcomes are heavily influenced by appropriate patient selection and preoperative risk stratification, areas in which the MELD 3.0 scoring system offers significant utility. Pre-TIPS MELD 3.0 scores are especially useful for identifying patients at the highest risk of poor outcomes. A retrospective review of 855 patients with cirrhosis who underwent TIPS between December 2011 and October 2019 assessed the prognostic performance of MELD 3.0, MELD, MELD-Na, Child-Pugh, and Freiburg Index of Post-TIPS Survival (FIPS) scores. The c-index for MELD 3.0 in predicting 3-month mortality was 0.727 (95% CI: 0.645–0.808), significantly outperforming MELD (0.663), MELD-Na (0.672), and FIPS (0.582) (p<0.05 for all). The Child-Pugh score showed slightly higher c-indices for 3-, 6-, and 12-month mortality but was comparable to MELD 3.0 overall. A MELD 3.0 score of 14 was suggested as a meaningful cutoff to distinguish between high- and low-risk patients.[24] Following TIPS placement, serial measurements of MELD 3.0 provide valuable dynamic prognostic information. An increase of 3 points in MELD-Na, which closely correlated with MELD 3.0, within 6 months after the procedure is associated with a 1.8-fold increase in long-term mortality, independent of the initial baseline score.[25] This finding highlights the importance of reevaluating transplant needs at 6 months. Indeed, according to the Advancing Liver Therapeutic Approaches (ALTA) retrospective study, among patients who achieved early transplant-free survival, 62% maintained a 1-year survival rate of 88% and a 3-year survival rate of 57%, even without transplantation.[25] This multicenter ALTA retrospective study included 1,127 adult patients who underwent TIPS, with a total follow-up of 2,040 person-years. Competing risk regression analyses demonstrated that both MELD-Na and MELD 3.0 were independently associated with post-TIPS mortality. Compared with MELD-Na<15, hazard ratios for mortality were 1.1 (p=0.42) for MELD-Na 15–19, 1.3 (p=0.04) for MELD-Na 20–24, and 1.7 (p<0.01) for MELD-Na≥25.[25] In the context of TIPS, this allows better identification of candidates for whom the procedure can serve as definitive therapy (“destination TIPS”) versus those who may require it as a bridge to transplantation. Notably, patients with stable MELD 3.0 scores after TIPS have low complication rates, with only an 8% rate of hepatic encephalopathy-related hospitalizations, supporting the long-term viability of TIPS in selected individuals.[25] Overall, MELD 3.0 serves a dual purpose in TIPS management: it guides initial risk stratification and enables ongoing prognostic monitoring. Integrating MELD 3.0 into both procedural planning and 6-month follow-up assessments allows clinicians to better evaluate transplant candidacy and avoid unnecessary listings for patients likely to achieve sustained transplant-free survival.[24–26] Findings from the ALTA group further support the implementation of MELD 3.0-guided reassessment protocols, potentially redefining TIPS from a bridge to transplantation to a long-term, standalone therapy in carefully selected patients.[25] Alcohol-Associated Hepatitis Alcohol-associated hepatitis (AH) remains a formidable clinical challenge, characterized by acute liver injury due to excessive alcohol consumption and associated with high morbidity and mortality. Severe AH, often defined by a Maddrey Discriminant Function (MDF) score of 32 or higher, carries a short-term mortality risk approaching 50% within 28 days, with overall 90-day mortality rates ranging from 30% to 40%.[27–30] The clinical course of severe AH is often complicated by multiorgan failure, particularly acute kidney injury (AKI), which is a major determinant of poor prognosis. Accurate risk stratification is therefore essential for guiding therapeutic decisions, including the use of corticosteroids and consideration for liver transplantation. Models such as the Age-Bilirubin-INR-Creatinine (ABIC) score, MDF, MELD, and MELD-Na have historically been used to estimate short-term mortality in AH.[27] However, these models have underestimated disease severity in malnourished individuals. By including factors such as serum sodium and albumin, which more accurately reflect the patient’s nutritional status and overall health, MELD 3.0 has addressed this limitation and improved risk assessment and prognosis.[3] In a large multinational retrospective cohort study that included 2,124 patients from 28 centers in 10 countries, MELD 3.0 outperformed MELD-Na and MDF in predicting 30-day and 90-day mortality, with area under the curve (AUC) values of 0.761 and 0.757, respectively. Importantly, the classification accuracy of MELD 3.0 was consistent across various geographic regions and patient subgroups, although its performance was comparable to that of the original MELD and ABIC scores. This may be attributed to differences in alcohol exposure, as well as environmental, genetic, and epigenetic factors. Notably, MELD 3.0 demonstrated clinical value in identifying patients at risk for severe multiorgan dysfunction, as it was the most accurate predictor of the need for renal replacement therapy (RRT) during hospitalization (AUC 0.844). Given that renal impairment is a key driver of mortality in AH, this predictive capability is clinically meaningful. The study also highlighted that 6-month survival remained poor, at only 57%, reflecting the aggressive natural history of severe AH despite advances in supportive care. Although further prospective validation is warranted, these findings support the integration of MELD 3.0 into routine clinical practice for AH, both for mortality risk stratification and for anticipating the need for intensive interventions such as RRT, thereby expanding its utility well beyond the transplantation setting.[31] Additionally, in a study conducted in 2024, MELD scores were applied at patient admission to evaluate AH severity and predict response to corticosteroids. The study found that patients with MELD scores greater than 30 showed poor or no response to corticosteroids (odds ratio, 2.42). This association exists because elevated MELD scores correlate with clinical factors such as age, cirrhosis, hypoalbuminemia, and RI, which collectively predict poor corticosteroid response. ROC curve analyses revealed that, compared with other scoring systems such as MDF, MELD-Na, ABIC, and the Glasgow Alcoholic Hepatitis Score (GAHS), MELD 3.0 had the highest AUC for predicting mortality at 1 month and 1 year. A MELD 3.0 threshold above 20 showed high sensitivity, at approximately 91%–92%, making it an important tool for early risk assessment and mortality prediction.[30] One important limitation to acknowledge is the inclusion of albumin in the MELD 3.0 calculation, particularly for patients with alcoholic hepatitis or renal insufficiency. These patients frequently receive albumin supplementation early in their clinical course, which may artificially elevate measured albumin levels and confound risk estimation. Although the model incorporates the correlation between albumin and creatinine, this potential source of bias remains clinically relevant. Hepatic Visceral Crisis in Patients with Solid Tumors Hepatic visceral crisis (HVC) is a fatal syndrome often observed in solid tumors of the breast, colorectal system, and pancreas and results from the rapid deterioration of liver function due to metastatic burden. This condition is reflected by elevated liver enzymes, hyperbilirubinemia (>1.5 times the upper limit), and clinical signs such as hepatocellular failure without biliary obstruction.[32,33] A unique study by Tay et al.[34] investigated the combined utility of MELD scoring systems and the Systemic Immune-Inflammatory Index (SII) in predicting outcomes in patients with solid tumors experiencing HVC. All three MELD variants—original MELD, MELD-Na, and MELD 3.0—showed considerable predictive significance in their descriptive investigation of 295 patients, with patients scoring ≥20 having an approximately two-fold higher risk of death. In these high-scoring groups, median overall survival was significantly lower: 1.28 versus 2.16 months for MELD 3.0 (p=0.039), 0.88 versus 1.44 months for original MELD (p<0.001), and 0.85 versus 1.64 months for MELD-Na (p<0.001). An SII ≥626.28 was also found to be a strong predictor of mortality, with 78.7% sensitivity and 100% specificity on ROC analysis. Cox regression identified several factors influencing survival, with MELD-Na ≥20 increasing the probability of death by 2.41-fold.[34] This study provides clinicians with useful, affordable, and objective tools for assessing prognosis in patients with cancer and liver disease, marking a significant advance in the application of MELD scoring beyond transplantation settings. The combination of MELD scores with inflammatory markers such as SII offers enhanced sensitivity and specificity while eliminating sex-based disparities in mortality estimation, positioning this approach as valuable for clinical decision-making in oncology practice. In addition, the study showed that the predictive performance of MELD, MELD-Na, and MELD 3.0 was comparable despite the inclusion of albumin in the MELD 3.0 model. Nonetheless, MELD 3.0 might be expected to perform better in HVC given the typically low albumin levels in these patients. This discrepancy highlights the need for further evaluation of MELD 3.0 in oncology-related hepatic dysfunction. As in the heart transplantation domain, evidence in this setting remains limited; to date, available data are confined to a single study, which limits generalizability and warrants further validation. Hepatic Hydrothorax Hepatic hydrothorax (HH) is a serious complication of advanced cirrhosis, characterized by the development of transudative pleural effusions in the absence of underlying cardiac or pulmonary disease. It affects approximately 5%–16% of patients with cirrhosis, particularly those with more advanced liver dysfunction, such as Child-Pugh class B or C.[35,36] Compared with cirrhosis with ascites alone, HH is associated with significantly poorer outcomes, with reported 1-year mortality rates ranging from 50% to 60%.[35,37,38] Median survival after HH onset is typically less than 1 year, and short-term mortality is notably high; studies have reported 30-day, 90-day, and 1-year mortality rates of 10%–29%, 26%–45%, and 51%–59%, respectively.[35,37,39] Crucially, emerging data suggest that patients with HH tend to die at lower MELD or MELD-Na scores than those with refractory ascites, implying that conventional MELD-based scoring may underestimate disease severity in these patients.[39,40] For instance, one study found that the median MELD score at death among patients with HH was 22.5, compared with 32.5 among patients with cirrhosis without HH.[40] This indicates that HH contributes additional mortality risk that is not fully captured by the MELD or MELD-Na scoring systems. Unfortunately, even MELD 3.0 has shown limited utility in accurately predicting mortality in patients with HH.[39,40] Spontaneous Bacterial Peritonitis Spontaneous bacterial peritonitis (SBP) is the most common bacterial infection encountered in patients with cirrhosis.[41] Its prevalence ranges from 1.5% to 3% in outpatients and may reach 10% to 30% in hospitalized patients with cirrhosis.[42] Microcirculatory changes due to cirrhosis and portal hypertension disrupt intestinal mucosal blood flow and compromise intestinal barrier integrity, facilitating the translocation of bacterial pathogens into the peritoneal cavity and leading to SBP.[43] It is important to recognize that infections such as SBP can increase the mortality rate fourfold in patients with cirrhosis.[44] Therefore, accurate prognostic tools are needed to enable early intervention and reduce mortality. Lin et al.[45] assessed the predictive power of several scoring systems for short-term mortality in patients with cirrhosis experiencing their first episode of SBP in a retrospective study. The performance of multiple scoring models, including CTP, MELD, MELD-Na, integrated MELD (iMELD), and MELD 3.0, was examined in a total of 327 patients. In-hospital mortality, as well as 3- and 6-month mortality after SBP diagnosis, were the main outcomes evaluated. MELD 3.0 outperformed the other models for 3-month mortality (AUROC=0.760) and in-hospital mortality (AUROC=0.786). Although MELD 3.0 did not demonstrate statistically significant superiority over previous MELD-based models (p>0.05 for all comparisons), it did significantly outperform the CTP score (p<0.001). The iMELD score had the highest AUROC (0.752) for predicting 6-month mortality and was significantly superior to CTP (p<0.0001), although its advantage over the other MELD-based scores was not statistically significant (p>0.05). Compared with more traditional scoring methods such as CTP, MELD 3.0 shows potential as a reliable model for predicting short-term mortality in patients with cirrhosis and SBP. Conclusion The MELD 3.0 score demonstrates notable prognostic utility across a variety of hepatic and extrahepatic clinical contexts. In cardiac transplantation, findings demonstrate the potential applicability of MELD 3.0 for predicting 6-month mortality and ICU length of stay. In acute variceal hemorrhage, although MELD 3.0 performs comparably to traditional scores such as MELD and Child-Turcotte-Pugh (CTP), its practical use is limited by calibration variability, making simpler tools more suitable in acute settings. Among patients with hepatocellular carcinoma and renal insufficiency, MELD 3.0 shows prognostic value but is surpassed by liver-specific scores such as ALBI. In TIPS procedures, MELD 3.0 improves patient selection and timing for transplant evaluation, supporting its use beyond traditional models. It also outperforms other scores in alcohol-associated hepatitis, particularly in assessing the need for renal replacement therapy and addressing sex- and nutrition-related disparities. In oncology, MELD 3.0 combined with inflammatory markers helps stratify risk in patients with hepatic visceral crisis. However, in hepatic hydrothorax, it underestimates mortality risk, highlighting the need for condition-specific tools. In spontaneous bacterial peritonitis, MELD 3.0 offers superior short-term mortality prediction, reinforcing its value in high-risk cirrhotic populations. For a concise overview, the main results are tabulated in Table 1. Overall, MELD 3.0 enhances prognostic accuracy but requires context-specific application to maximize its clinical impact. Before MELD 3.0 can be universally implemented, large-scale prospective studies across multiple regions and transplant settings are required to confirm its generalizability and validate its superiority over existing scoring systems. Table 1Key findings overviewClinical conditionPrimary endpointComparison to other scoresClinical utilityOrthotopic Heart Transplantation6-month mortalityNot compared to other MELD variantsPredicts ICU stay (5 days difference, p=0.01)Acute Variceal Hemorrhage6-week mortalityComparable to traditional scoresLimited by calibration variability in acute settingsHCC with Renal InsufficiencyOverall survivalInferior to ALBI-based models (AICc: 11,281.79)Moderate predictive value, inferior to ALBI-based modelsTIPS Procedures3-month mortalitySuperior to prior MELD variants (p<0.05)Dynamic monitoring; 3-point increase = 1.8x mortality riskAlcohol-Associated Hepatitis30-day & 90-day mortalityComparable to the MELD and ABIC scoresBest predictor of RRT need (AUC 0.844)Hepatic Visceral CrisisOverall survivalComparable to MELD-Original and MELD-NaEnhanced when combined with SII; 2-fold mortality riskHepatic HydrothoraxMortalityInferior across MELD variantsUnderestimates the mortality risk in this group of patientsSpontaneous Bacterial PeritonitisIn-hospital & 3-month mortalityComparable to other MELD variants (p>0.05)Reliable for short-term mortality predictionMELD: Model for end-stage liver disease; HCC: Hepatocellular carcinoma; ALBI: Albumin-bilirubin; AICc: Akaike information criterion; TIPS: Transjugular intrahepatic portosystemic shunt; ABIC: Age-bilirubin-INR-creatinine; RRT: Renal replacement therapy; AUC: Area under the curve; SII: Systemic immune-inflammatory index. Key findings overview MELD: Model for end-stage liver disease; HCC: Hepatocellular carcinoma; ALBI: Albumin-bilirubin; AICc: Akaike information criterion; TIPS: Transjugular intrahepatic portosystemic shunt; ABIC: Age-bilirubin-INR-creatinine; RRT: Renal replacement therapy; AUC: Area under the curve; SII: Systemic immune-inflammatory index.